By Topic
New Murchison Gold (ASX: NMG): Pay for the Current Gold, Get the Exploration Potential for Free
New Murchison Gold Limited is a small Australian gold producer operating the Crown Prince mine in Western Australia. The company recently transitioned from exploration to production and is generating strong cash flow from high-grade ore sold to Westgold Resources Limited. Exploration at nearby targets and potential underground mining could extend the project’s life and add future growth potential.
LaserBond (ASX: LBL): Undervalued Industrial Compounder Ready to Re-Rating?
LaserBond (ASX: LBL) is a niche industrial tech company that extends the life of heavy equipment for sectors like mining and energy. It delivers strong margins and cash flow, with growth driven by acquisitions, OEM partnerships, and rising demand for refurbishment solutions. The stock trades on reasonable valuations with a dividend, offering upside if growth and momentum continue.
How much higher can the breakout in Liontown's (ASX: LTR) share price take it?
Liontown Resources has rallied on stronger lithium prices, improving production at Kathleen Valley, and a healthier balance sheet after reducing debt. Rising EV and battery demand plus new offtake deals have lifted sentiment. The stock is now approaching key resistance around A$2.20, where the next breakout or pullback will likely be decided.
Massive Volume Surge in Botanix Pharmaceuticals (ASX: BOT): Is it finally finding a bottom?
Botanix Pharmaceuticals has seen a sharp volume spike after a major share price decline, hinting at possible bottoming. While Sofdra sales are growing and funding has improved liquidity, the stock remains in a downtrend, with any recovery dependent on stronger fundamentals and a break above key resistance.
PlaySide Studios (ASX: PLY) Strategic Pivot: Where can its share price go after the recent volatility?
PlaySide Studios is shifting from contract development to original IP and publishing to boost margins and growth. Strong partnerships and a solid pipeline support optimism, but revenue volatility and past unprofitability keep investor sentiment cautious.
Is Orthocell's (ASX: OCC) Recent Share Price Decline a Warning Sign or a Buying Signal?
Orthocell is a regenerative medicine company expanding Remplir globally, but investors remain cautious because revenue growth is uneven, the business is still loss-making, and U.S. uptake may take time, leaving the stock a higher-risk turnaround opportunity.
...